Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials

References

• Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102:1K–34K.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547–563.
   PubMed Web of Science ®Google Scholar
• McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs. 2011;71:1917–1946.
   PubMed Web of Science ®Google Scholar
• Shipman KE, Strange RC, Ramachandran S. Use of fibrates in the metabolic syndrome: a review. World J Diabetes. 2016;7:74–88.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Maki KC, Orringer CE, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9:S1–122.e1.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9:129–169.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res. 2014;56:47–66.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Giua R, Pedone C, et al. Fibrate therapy and flow-mediated dilation: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016;111:163–179.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Watts GF. Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis. 2013;230:110–120.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99:3C–18C.
   PubMed Web of Science ®Google Scholar
• Bobek LA, Levine MJ. Cystatins-inhibitors of cysteine proteinases. Crit Rev Oral Biol Med. 1992;3:307–332.
   PubMedGoogle Scholar
• Zi M, Xu Y. Involvement of cystatin C in immunity and apoptosis. Immunol Lett. 2018;196:80–90.
   PubMed Web of Science ®Google Scholar
• Menon V, Shlipak MG, Wang X, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med. 2007;147:19–27.
   PubMed Web of Science ®Google Scholar
• Garcia-Carretero R, Vigil-Medina L, Mora-Jimenez I, et al. Cardiovascular risk assessment in prediabetic patients in a hypertensive population: the role of cystatin C. Diabetes Metab Syndr. 2018;12:625–629.
   PubMed Web of Science ®Google Scholar
• Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function-a review. Clin Chem Lab Med. 1999;37:389–395.
   PubMed Web of Science ®Google Scholar
• Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155.
   PubMed Web of Science ®Google Scholar
• Bostom A, Brosnan JT, Hall B, et al. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis. 1995;116:59–62.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Handbook for systematic reviews of interventions (version 5.0.2). London: The Cochrane Collboration; 2009.
   Google Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. (1471-2288 (Electronic)). BMC Med Res Methodol. 2014;14:135.
   PubMed Web of Science ®Google Scholar
• Sahebkar A. Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol. 2013;32:188–198.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Serban C, Mikhailidis DP, et al. Association between statin use and plasma d-dimer levels: a systematic review and meta-analysis of randomised controlled trials. Thromb Haemost. 2015;114:546–557.
   PubMed Web of Science ®Google Scholar
• Serban C, Sahebkar A, Ursoniu S, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep. 2015;5:9902.
   PubMed Web of Science ®Google Scholar
• Atkin SL, Katsiki N, Banach M, et al. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials. Journal of Diabetes and Its Complications. 2017;31:1458–1464.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463.
   PubMed Web of Science ®Google Scholar
• Ansquer JCDR, Caussé E, Crimet D, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51:904–913.
   PubMed Web of Science ®Google Scholar
• Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999;354:219–220.
   PubMed Web of Science ®Google Scholar
• Dierkes JWS, Kunstmann S, Banditt P, et al. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis. 2001;158:161–164.
   PubMed Web of Science ®Google Scholar
• Forsblom CHA, Leinonen ES, Sundvall J, et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care. 2010;33:215–220.
   PubMed Web of Science ®Google Scholar
• Foucher CAP, Reichert P, Berli M, et al. New fixed-dose combinations of fenofibrate/simvastatin therapy significantly improve the lipid profile of high-risk patients with mixed dyslipidemia versus monotherapies. Cardiovasc Ther. 2015;33:329–337.
   PubMed Web of Science ®Google Scholar
• Ishibashi SAH, Yokote K, Araki E, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12:173–184.
   PubMed Web of Science ®Google Scholar
• Mychaleckyj JCCT, Nayak U, Buse J, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012;35:1008–1014.
   PubMed Web of Science ®Google Scholar
• Ncube V, Starkey B, Wang T. Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C. Ann Clin Biochem. 2012;49:491–493.
   PubMed Web of Science ®Google Scholar
• Westphal SDJ, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet. 2001;258:39–40.
   Google Scholar
• Sahebkar A, Pirro M, Reiner Z, et al. A systematic review and meta-analysis of controlled trials on the effects of statin and fibrate therapies on plasma homocysteine lev. Cmc. 2016;23:4490–4503.
   PubMed Web of Science ®Google Scholar
• Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60:2061–2071.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Exp Opin Pharmacother. 2014;15:493–503.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Watts GF. Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster. Diabetes Obes Metab. 2014;16:780–792.
   Web of Science ®Google Scholar